Fabrizio Galimberti
Papers
1
Total Citations
67
H-Index
1
About
Fabrizio Galimberti is a leading cancer biologist whose research focuses on the molecular mechanisms driving lung cancer, particularly the role of cyclin-dependent kinases (Cdks) and their associated cyclins in tumor growth. His most cited work, "Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase Catastrophe" (2009, 67 citations), represents a pivotal contribution to the field. In this study, Galimberti and his team uncovered a previously unrecognized consequence of inhibiting the cyclin E-Cdk-2 complex: the induction of anaphase catastrophe, a novel cell death mechanism distinct from apoptosis. This discovery not only provided critical insight into how lung cancer cells respond to targeted therapies but also opened new avenues for chemopreventive strategies. By demonstrating that disrupting this complex can effectively repress lung cancer growth, Galimberti’s work has helped shift the paradigm toward targeting cell cycle regulators in cancer treatment. His research continues to influence the development of next-generation therapeutics, making him a key figure in translational oncology. With a strong track record of high-impact publications, Galimberti remains at the forefront of efforts to translate basic cell cycle biology into clinical applications for lung cancer patients.
Research Focus
Key Achievements
Top Papers
- 1